Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage

Keyphrases

• Aflibercept 50%
• Biomimetic Peptide 25%
• C-Met 25%
• Choroidal 25%
• Collagen IV 100%
• Complex Formation 25%
• Current Treatment 25%
• Derived Peptide 100%
• Human Eye 25%
• Integrin 25%
• Intraocular Injection 75%
• Ischemic Retinopathy 50%
• Macular Edema 25%
• Mimetic Peptide 25%
• Mouse Model 25%
• Multiple Receptor 25%
• Multitarget Therapy 25%
• Myopic Choroidal Neovascularization (mCNV) 25%
• Neovascular Age-related Macular Degeneration (nAMD) 50%
• Neutralizing Proteins 50%
• Ocular Neovascularization 100%
• Optimal Signals 25%
• Phosphorylation 25%
• Platelet-derived Growth Factor Receptor (PDGFR) 25%
• Predictive Models 50%
• Rabbit Eye 25%
• Retinal Neovascularization 75%
• Suboptimal Outcome 25%
• Tyrosine Kinase 100%
• Ubiquitination 25%
• Vascular Disease 25%
• Vascular Endothelial Growth Factor 100%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 50%
• Vascular Leakage 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Aflibercept 50%
• Integrin 25%
• Leporidae 25%
• Macular Edema 25%
• Mouse Model 25%
• Neovascularization (Pathology) 100%
• Protein Tyrosine Kinase 100%
• Receptor 50%
• Retina Neovascularization 25%
• Retinopathy 50%
• Subretinal Neovascularization 75%
• Vascular Disease 25%
• Vasculotropin 100%
• Wet Macular Degeneration 50%

Neuroscience

• Aflibercept 50%
• Age-Related Macular Degeneration 50%
• Choroidal Neovascularization 25%
• Complex Formation 25%
• Integrin 25%
• Internalization 25%
• Receptor 50%
• Receptor Tyrosine Kinase 100%
• Retinal Disease 50%
• Tyrosine Kinase 100%
• Ubiquitination 25%
• Vascular Disease 25%
• Vascular Endothelial Growth Factor 100%